Skip to main content
Erschienen in: Journal of Cancer Education 2/2020

04.01.2019

Impact of Survivorship Care Plans and Planning on Breast, Colon, and Prostate Cancer Survivors in a Community Oncology Practice

verfasst von: Alexandra Hua, Mary E. Sesto, Xiao Zhang, Timothy R. Wassenaar, Amye J. Tevaarwerk

Erschienen in: Journal of Cancer Education | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

With a growing number of cancer survivors, survivorship care plans (SCPs) are recommended to communicate information about late effects of treatment and follow-up care. Community oncology practices follow 85% of adult cancer survivors but report more difficulty in providing SCPs compared to academic centers. Our objective was to evaluate the impact of delivering SCPs in a community oncology practice by examining awareness of SCP receipt as well as how provision affects survivors’ perception of care quality and of their condition. Survivors who accepted a SCP as standard of care were recruited from a community oncology practice in the Midwest and completed surveys prior to SCP provision (baseline) and 4 weeks later (follow-up). Within-survivor changes in knowledge of SCP receipt, satisfaction and perceived care coordination were assessed. Thirty cancer survivors (breast, colon, and prostate) completed the baseline survey, while 24 completed the follow-up survey (80% response rate). Participants reported receiving SCPs and treatment summaries more frequently at follow-up after receiving a SCP. At follow-up, there was a significant increase in survivor activation and involvement in care along with satisfaction of knowledge of care. Communication about and during SCP provision may need to be clearer: 34% of survivors could not correctly identify SCP receipt in this study. This may place these survivors at a disadvantage, if this leads to less awareness of important information regarding follow-up surveillance and management. Of those aware of SCP receipt, SCP provision had positive impacts in this small, short-term study.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Institute, National Cancer (2017) Cancer statistics. Accessed 2018 Institute, National Cancer (2017) Cancer statistics. Accessed 2018
2.
Zurück zum Zitat Medicine, Institute of, and National Research Council (2006) From cancer patient to cancer survivor: lost in transition. The National Academies Press, Washington, DC Medicine, Institute of, and National Research Council (2006) From cancer patient to cancer survivor: lost in transition. The National Academies Press, Washington, DC
8.
Zurück zum Zitat Society, American Cancer. 2018. Survivorship care plans. Accessed 2018. Society, American Cancer. 2018. Survivorship care plans. Accessed 2018.
9.
Zurück zum Zitat Birken SA, Mayer DK, Weiner BJ (2013) Survivorship care plans: prevalence and barriers to use. J Cancer Educ 28(2):290–296CrossRef Birken SA, Mayer DK, Weiner BJ (2013) Survivorship care plans: prevalence and barriers to use. J Cancer Educ 28(2):290–296CrossRef
11.
Zurück zum Zitat de Rooij BH, Ezendam NPM, Nicolaije KAH, Caroline Vos M, Pijnenborg JMA, Boll D, Boss EA, Hermans RHM, Engelhart KCM, Haartsen JE, Pijlman BM, van Loon-Baelemans IEAM, Mertens HJMM, Nolting WE, van Beek JJ, Roukema JA, Kruitwagen RFPM, van de Poll-Franse LV (2017) Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2-year follow-up - the ROGY care trial. Gynecol Oncol 145(2):319–328. https://doi.org/10.1016/j.ygyno.2017.02.041. CrossRefPubMed de Rooij BH, Ezendam NPM, Nicolaije KAH, Caroline Vos M, Pijnenborg JMA, Boll D, Boss EA, Hermans RHM, Engelhart KCM, Haartsen JE, Pijlman BM, van Loon-Baelemans IEAM, Mertens HJMM, Nolting WE, van Beek JJ, Roukema JA, Kruitwagen RFPM, van de Poll-Franse LV (2017) Effects of survivorship care plans on patient reported outcomes in ovarian cancer during 2-year follow-up - the ROGY care trial. Gynecol Oncol 145(2):319–328. https://​doi.​org/​10.​1016/​j.​ygyno.​2017.​02.​041.​ CrossRefPubMed
12.
Zurück zum Zitat Tevaarwerk AJ, Wisinski KB, Buhr KA, Njiaju UO, Tun M, Donohue S, Sekhon N, Yen T, Wiegmann DA, Sesto ME (2014) Leveraging electronic health record systems to create and provide electronic cancer survivorship care plans: a pilot study. J Oncol Pract 10(3):e150–e159CrossRef Tevaarwerk AJ, Wisinski KB, Buhr KA, Njiaju UO, Tun M, Donohue S, Sekhon N, Yen T, Wiegmann DA, Sesto ME (2014) Leveraging electronic health record systems to create and provide electronic cancer survivorship care plans: a pilot study. J Oncol Pract 10(3):e150–e159CrossRef
16.
Zurück zum Zitat Parry C, Beckjord E, Moser RP, Vieux SN, Padgett LS, Hesse BW (2015) It takes a (virtual) village: crowdsourcing measurement consensus to advance survivorship care planning. Transl Behav Med 5(1):53–59CrossRef Parry C, Beckjord E, Moser RP, Vieux SN, Padgett LS, Hesse BW (2015) It takes a (virtual) village: crowdsourcing measurement consensus to advance survivorship care planning. Transl Behav Med 5(1):53–59CrossRef
17.
Zurück zum Zitat Glasgow RE, Wagner EH, Schaefer J, Mahoney LD, Reid RJ, Greene SM (2005) Development and validation of the patient assessment of chronic illness care (PACIC). Med Care 43(5):436–444CrossRef Glasgow RE, Wagner EH, Schaefer J, Mahoney LD, Reid RJ, Greene SM (2005) Development and validation of the patient assessment of chronic illness care (PACIC). Med Care 43(5):436–444CrossRef
19.
Zurück zum Zitat Cleary PD, Edgman-Levitan S (1997) Health care quality. Incorporating consumer perspectives. JAMA 278(19):1608–1612CrossRef Cleary PD, Edgman-Levitan S (1997) Health care quality. Incorporating consumer perspectives. JAMA 278(19):1608–1612CrossRef
21.
23.
Zurück zum Zitat Hershman DL, Greenlee H, Awad D, Kalinsky K, Maurer M, Kranwinkel G, Brafman L, Jayasena R, Tsai WY, Neugut AI, Crew KD (2013) Randomized controlled trial of a clinic-based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Res Treat 138(3):795–806. https://doi.org/10.1007/s10549-013-2486-1. CrossRefPubMed Hershman DL, Greenlee H, Awad D, Kalinsky K, Maurer M, Kranwinkel G, Brafman L, Jayasena R, Tsai WY, Neugut AI, Crew KD (2013) Randomized controlled trial of a clinic-based survivorship intervention following adjuvant therapy in breast cancer survivors. Breast Cancer Res Treat 138(3):795–806. https://​doi.​org/​10.​1007/​s10549-013-2486-1.​ CrossRefPubMed
Metadaten
Titel
Impact of Survivorship Care Plans and Planning on Breast, Colon, and Prostate Cancer Survivors in a Community Oncology Practice
verfasst von
Alexandra Hua
Mary E. Sesto
Xiao Zhang
Timothy R. Wassenaar
Amye J. Tevaarwerk
Publikationsdatum
04.01.2019
Verlag
Springer US
Erschienen in
Journal of Cancer Education / Ausgabe 2/2020
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-018-1457-y

Weitere Artikel der Ausgabe 2/2020

Journal of Cancer Education 2/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.